Tango Therapeutics’ experimental drug combined with Revolution Medicines’ Rasonque shrank tumors in 82% of patients with a specific type of advanced pancreatic cancer. At nine months, 88% remained alive without disease progression; the targeted regimen uses no chemotherapy.